2 reports

  • 11.4.1. PUBLICATIONS ON DPP4 INHIBITORS: DISTRIBUTION BY
  • DPP4 INHIBITORS: PIPELINE DRUGS

INTRODUCTION Diabetes, considered to be the most common metabolic disorder in humans, is ranked among the top ten fatal diseases in the US. The increasing incidence, growing prevalence and the progressive nature of the disease has spurred several pharmaceutical companies to develop novel approaches / therapies to provide better treatment...

  • Gliptins
  • North America
  • United States
  • Boehringer Ingelheim GmbH
  • Sanofi S.A.

DPP IV Inhibitors

4091 4500 3477

MARKET ##.

  • Gliptins
  • APAC
  • United States
  • World
  • Company Sales